| Name | Title | Contact Details |
|---|
Evolve BioSystems is a spin-out from the Foods For Health Institute (FFHI) at the University of California, Davis. The company builds on more than a decade of research into the infant gut microbiome and its unique interaction with breast milk components, established by the founding scientists including Bruce German, David Mills, Carlito Lebrilla, Daniela Barile and Samara Freeman. Their fundamental research and translational clinical trials have been enabled by more than $15 million in federal and private grants since 2004. Under the leadership of CEO Dr. David Kyle, Evolve completed a $1 million seed funding round in mid-2014, a $9 million Series A round in August 2015 and most recently a $20 million Series B capital raise in 2017. Evolve has now successfully completed a milestone proof-of-concept study to demonstrate the efficacy of its initial proprietary offering, with a series of upcoming trials scheduled across both human and animal health applications. With a strong portfolio of intellectual property developed at UC Davis, a world-class management team plus blue-chip investors, and an unwavering dedication to allowing science to direct our product development, Evolve continues to expand it`s pipeline of next generation microbiome-based solutions to establish, restore, and maintain a healthy gut microbiome.
Roswell Biotechnologies is a molecular electronics company transforming DNA sequencing with their latest platform, designed to deliver the disruptive performance required for future biomedical and industrial applications.
Regenacy Pharmaceuticals is developing a novel, disease-modifying approach to treating peripheral neuropathies that goes beyond pain and symptom management to restore peripheral nerve function.
Organogenesis Inc. is a Canton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Tolerx is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.